Sulfisoxazole

Sulfisoxazole is a sulfonamide antibiotic and nonpeptide endothelin (ET) receptor antagonist (IC50s = 0.6 and 22 µM for the ETA and ETB receptors, respectively). It inhibits the growth of Gram-positive and Gram-negative bacteria in vitro, including S. pneumoniae, B. subtilis, S. epidermidis, E. coli, and K. pneumoniae (MICs = 1.95, 0.98, 7.81, 62.5, and 7.81 µg/mL, respectively). Sulfisoxazole inhibits phosphoinositide turnover stimulated by endothelin-1 (ET-1, Cay-24127) in TE671 cells. It inhibits ET-induced contraction of rat pulmonary artery rings ex vivo when used at concentrations of 0.1 and 1 mM. Sulfisoxazole (1,000 mg/kg per day) reduces atrial natriuretic peptide levels in myocytes and plasma and increases survival in a rat model of pulmonary hypertension induced by monocrotaline (MCT, Cay-16666) as well as blocks MCT-induced increases in pulmonary artery blood pressure when administered at doses of 300 and 1,000 mg/kg.Formal Name: 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-benzenesulfonamide. CAS Number: 127-69-5. Synonyms: NSC 13120, NSC 33807, NSC 38588, NSC 683536, Sulfafurazole. Molecular Formula: C11H13N3O3S. Formula Weight: 267.3. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 50 mg/ml, DMSO: 50 mg/ml, DMSO:PBS (pH 7.2) (1:9): 0.1 mg/ml, Ethanol: 1 mg/ml. SMILES: NC1=CC=C(S(NC2=C(C)C(C)=NO2)(=O)=O)C=C1. InChi Code: InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3. InChi Key: NHUHCSRWZMLRLA-UHFFFAOYSA-N.